{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:36:22Z","timestamp":1787877382588,"version":"build-2784847793"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL), characterized by heterogeneous clinical behavior and variable prognosis. Accurate prognostication is essential for risk-adapted management. This review synthesizes emerging evidence on prognostic factors in MF and SS, with a focus on recent genomic advances. Traditional prognostic frameworks are outlined, highlighting the prognostic impact of demographics, stage, clinical features, and histologic findings. More advanced prognostics are then outlined, including genomic alterations and impact of the tumor microenvironment. We highlight realms in which integration of traditional and more biological prognostic frameworks can support more individualized treatment strategies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1881519","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:31:26Z","timestamp":1782887486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Established and emerging prognostic factors in mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Viviane","family":"Liao","sequence":"first","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Stuver","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir","family":"Geller","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]},{"name":"Department of Dermatology, Weill Cornell Medicine","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502","article-title":"Who-eortc classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous t cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous t-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5045\/br.2023.2023023","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"58","author":"Lee","year":"2023","journal-title":"Blood Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1284045","article-title":"Advances in the treatment of mycoses fungoides and S\u00e9zary syndrome: a narrative update in skin-directed therapies and immune-based treatments","volume":"14","author":"Stuver","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12349","article-title":"Mycosis fungoides and S\u00e9zary syndrome: current challenges in assessment, management and prognostic markers","volume":"57","author":"Hughes","year":"2016","journal-title":"Australas J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/ European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15865","article-title":"Characteristics and outcomes of 727 patients with mycosis fungoides and S\u00e9zary syndrome from a Brazilian cohort","volume":"61","author":"Miyashiro","year":"2022","journal-title":"Int J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2634","article-title":"Prognostic factors and survival outcomes among patients with mycosis fungoides in China: a 12-year review","volume":"159","author":"Chen","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029628","article-title":"A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification","volume":"146","author":"Scarisbrick","year":"2025","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic mode","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01549","article-title":"Efficacy and safety of denileukin diftitox-Cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"43","author":"Foss","year":"2025","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.2522","article-title":"Lacutamab in patients with relapsed and refractory S\u00e9zary syndrome: long-term follow-up from the TELLOMAK phase 2 trial","volume":"43","author":"Porcu","year":"2025","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19647","article-title":"Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies","volume":"205","author":"Campbell","year":"2024","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023584","article-title":"Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify patients with S\u00e9zary syndrome with low blood burden","volume":"144","author":"Chrisman","year":"2024","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34579","article-title":"Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: a retrospective cohort study","volume":"129","author":"Allen","year":"2023","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2191","article-title":"T-cell receptor gene rearrangement clonality, flow cytometry status, and associated outcomes in early-stage cutaneous T-cell lymphoma","volume":"157","author":"Marks","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with S\u00e9zary syndrome","volume":"134","author":"Gao","year":"2019","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1016\/j.clml.2025.08.008","article-title":"Skin response to mogamulizumab in patients with mycosis fungoides and Sezary syndrome: a retrospective, real world cohort","volume":"25","author":"Christensen","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.2.191","article-title":"Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients","volume":"138","author":"van Doorn","year":"2002","journal-title":"Arch Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.6.738","article-title":"Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma","volume":"144","author":"Gerami","year":"2008","journal-title":"Arch Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14528","article-title":"Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials","volume":"21","author":"Farabi","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.4372","article-title":"Association of a proposed new staging system for folliculotropic mycosis fungoides with prognostic variables in a US cohort","volume":"157","author":"Charli-Joseph","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.009","article-title":"New insights into folliculotropic mycosis fungoides (FMF): a single-center experience","volume":"75","author":"Hodak","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"van de Donk","year":"2012","journal-title":"MAbs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa261","article-title":"Prognostic significance of CD30 in transformed mycosis fungoides","volume":"156","author":"Travaglino","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223570","article-title":"The role of the immune phenotype in tumor progression and prognosis of patients with mycosis fungoides: a quantitative immunohistology whole slide approach","volume":"11","author":"Aulasevich","year":"2022","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19796","article-title":"Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and S\u00e9zary syndrome","volume":"185","author":"Calvani","year":"2021","journal-title":"Br J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71151","article-title":"GATA3 as a prognostic marker in early-stage classical mycosis fungoides: association with disease progression and survival outcomes","volume":"14","author":"Wen","year":"2025","journal-title":"Cancer Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/cup.13375","article-title":"Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation","volume":"46","author":"Raghavan","year":"2019","journal-title":"J Cutan Pathol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/DAD.0000000000002898","article-title":"Differential expression of p53 in mycosis fungoides, Sezary syndromes, and their transformed forms","volume":"47","author":"Courtois","year":"2025","journal-title":"Am J Dermatopathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.70070","article-title":"Immunoprofiling reveals GATA3 as a prognostic marker in transformed mycosis fungoides","volume":"53","author":"Souza","year":"2026","journal-title":"J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-\u03baB and nuclear factor of activated T cells pathways","volume":"182","author":"P\u00e9rez","year":"2020","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21063","article-title":"Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and S\u00e9zary syndrome: association with disease stage and clinical outcome","volume":"187","author":"Di Raimondo","year":"2022","journal-title":"Br J Dermatol"},{"key":"B53","unstructured":"50 Mg Powder for Concentrate for Solution for Infusion\n          \n          \n          \n          2026"},{"key":"B54","unstructured":"4 Mg\/Ml Concentrate for Solution for Infusion"},{"key":"B55","unstructured":"25 Mg\/Ml Concentrate for Solution for Infusion"},{"key":"B56","unstructured":"Press Release"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.12.018","article-title":"Poorer prognosis of African-Americans with mycosis fungoides: an analysis of the SEER dataset, 1988\u20132008","volume":"14","author":"Nath","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jaad.2017.04.1137","article-title":"Racial disparity in mycosis fungoides: an analysis of 4495 cases from the US National Cancer Database","volume":"77","author":"Su","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.017","article-title":"Racial disparities in mycosis fungoides\/S\u00e9zary syndrome-a single-center observational study of 292 patients","volume":"24","author":"Gandham","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae039","article-title":"Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study","volume":"190","author":"Trum","year":"2024","journal-title":"Br J Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.05.002","article-title":"Racial and socioeconomic disparities in cutaneous T-cell lymphoma survival: insights from the National Cancer Database","volume":"9","author":"Allen","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.09.074","article-title":"Racial differences in mycosis fungoides and S\u00e9zary syndrome: A multicenter cohort study","volume":"94","author":"Allen","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1779259","article-title":"Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL)","volume":"61","author":"Allen","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.073","article-title":"Outcomes and prognostic factors in African American and black patients with mycosis fungoides\/S\u00e9zary syndrome: retrospective analysis of 157 patients from a referral cancer center","volume":"83","author":"Geller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5424","article-title":"Racial disparities in mycosis fungoides - from self-reported race to genetic ancestry analysis","volume":"146","author":"Liao","year":"2025","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-020-00380-5","article-title":"Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological feature","volume":"10","author":"Argyropoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009655","article-title":"Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12943-021-01419-2","article-title":"Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma","volume":"20","author":"Rindler","year":"2021","journal-title":"Mol Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012125","article-title":"Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression","volume":"8","author":"Fl\u00e9chon","year":"2024","journal-title":"Blood Adv"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182984","article-title":"Integrative mutational landscape of mycosis fungoides using a national genomics repository","volume":"17","author":"Saglimbeni","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22679","article-title":"Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides","volume":"57","author":"Bastidas Torres","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.4688","article-title":"JAK2 fusions in adult patients with mycosis fungoides and CD30 lymphoproliferative disorders","volume":"162","author":"Geller","year":"2026","journal-title":"JAMA Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215512","article-title":"Targeted deep sequencing of mycosis fungoides reveals intracellular signaling pathways associated with aggressiveness and large cell transformation","volume":"13","author":"Wobser","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B77","article-title":"MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma","volume":"34","author":"Ralfkiaer","year":"2014","journal-title":"Anticancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788950","article-title":"Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study","volume":"131","author":"Lindahl","year":"2018","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-throughput sequencing of the T cell receptor \u03b2 gene identifies aggressive early-stage mycosis fungoides","volume":"10","author":"De Masson","year":"2018","journal-title":"Sci Transl Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/jamadermatol.2025.4081","article-title":"T-cell receptor clonotypes and aggressive subtypes in cutaneous T-cell lymphoma","volume":"162","author":"Crisan","year":"2026","journal-title":"JAMA Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant inflammation in cutaneous T\u2010cell lymphoma\u2014a hostile takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-023-00692-w","article-title":"New molecular and biological markers in cutaneous T cell lymphoma: therapeutic implications","volume":"18","author":"Luna","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030746","article-title":"Mycosis fungoides and S\u00e9zary syndrome: microenvironment and cancer progression","volume":"15","author":"Dobos","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.200","article-title":"Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression","volume":"146","author":"Samimi","year":"2010","journal-title":"Arch Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in S\u00e9zary syndrome and mycosis fungoides","volume":"48","author":"Cetin\u00f6zman","year":"2012","journal-title":"Arch Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12873","article-title":"The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides","volume":"25","author":"Furudate","year":"2016","journal-title":"Exp Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014495","article-title":"Spatial transcriptomics of progression gene signature and tumor microenvironment leading to progression in mycosis fungoides","volume":"9","author":"Choi","year":"2025","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415638","article-title":"Mast cells play a protumorigenic role in primary cutaneous lymphoma","volume":"120","author":"Rabenhorst","year":"2012","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00403-024-02909-1","article-title":"Prognostic implications of blood eosinophilia and tissue eosinophil infiltration in mycosis fungoides: a retrospective cohort study","volume":"316","author":"Jung","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1474564","article-title":"The cancer-associated fibroblasts interact with Malignant T cells in mycosis fungoides and promote the disease progression","volume":"15","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-02018-1","article-title":"Cutaneous T cell lymphoma atlas reveals Malignant TH2 cells supported by a B cell-rich tumor microenvironment","volume":"25","author":"Li","year":"2024","journal-title":"Nat Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3775","article-title":"Role of B-cells in mycosis fungoides","volume":"101","author":"Nielsen","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2021.33.6.487","article-title":"The role of tumor microenvironment in mycosis fungoides and s\u00e9zary syndrome","volume":"33","author":"Liu","year":"2021","journal-title":"Ann Dermatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/cells12151944","article-title":"A microenvironment-related nine-gene signature may predict survival in mycosis fungoides patients at diagnosis","volume":"12","author":"Alberti-Violetti","year":"2023","journal-title":"Cells"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1881519\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:31:38Z","timestamp":1782887498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1881519\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":96,"alternative-id":["10.3389\/fonc.2026.1881519"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1881519","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1881519"}}